Marc van Dijk
Chief Tech/Sci/R&D Officer at MINK THERAPEUTICS, INC.
Net worth: 24 846 $ as of 30/03/2024
Profile
Marc van Dijk is currently the Chief Scientific Officer at MiNK Therapeutics, Inc. He previously held positions as the Director of Applied Research & Development at Fujirebio Europe NV, Chief Scientific Officer at Medarex, Inc., Chief Technology Officer at Agenus, Inc., Scientist at the University of California, Berkeley, Chief Technology Officer at 4-Antibody AG, Vice President of Antibody Technology at Genmab, Inc., and Principal at the University Medical Center of Utrecht.
Dr. van Dijk obtained his doctorate degree from the University of Utrecht in 1992.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MINK THERAPEUTICS, INC.
0.08% | 15/01/2024 | 27,363 ( 0.08% ) | 24 846 $ | 30/03/2024 |
Marc van Dijk active positions
| Companies | Position | Start |
|---|---|---|
| MINK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 29/02/2020 |
Former positions of Marc van Dijk
| Companies | Position | End |
|---|---|---|
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Chief Tech/Sci/R&D Officer | 31/10/2008 |
Genmab, Inc.
 Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | Chief Tech/Sci/R&D Officer | 31/12/2004 |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Chief Tech/Sci/R&D Officer | - |
| University Medical Center of Utrecht | Corporate Officer/Principal | - |
Training of Marc van Dijk
| University of Utrecht | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AGENUS INC. | Health Technology |
| MINK THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
4-Antibody AG
 4-Antibody AG Pharmaceuticals: MajorHealth Technology 4-Antibody AG was discovers and develops drugs. The company was founded in 2002 and headquartered in Basel, Switzerland. | Health Technology |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | Commercial Services |
- Stock Market
- Insiders
- Marc van Dijk
